Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease

Ann Hepatol. Mar-Apr 2021;21:100212. doi: 10.1016/j.aohep.2020.04.012. Epub 2020 Jun 6.

Abstract

The obesity pandemic that affects the global population generates one of the most unfavorable microenvironmental conditions in the hepatocyte, which triggers the metabolic hepatopathy known as non-alcoholic fatty liver; its annual rates increase in its prevalence and does not seem to improve in the future. The international consortia, LITMUS by the European Union and NIMBLE by the United States of America, have started a race for the development of hepatic steatosis and steatohepatitis reliable biomarkers to have an adequate diagnosis. MicroRNAs have been proposed as diagnostic and prognostic biomarkers involved in adaptation to changes in the liver microenvironment, which could improve clinical intervention strategies in patients with hepatic steatosis.

Keywords: Epigenetics; NAFLD; NASH; miRNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't